Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-06835375 in SLE or RA
NCT03334851Phase 1Completed
- Sponsor
- Pfizer
- Start
- Nov 2017
- Primary completion
- Feb 2022
- Modality
- Antibody Conjugates, scFv Fragments, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PF-06835375 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA) (14 cohorts), sponsored by Pfizer. Primary endpoints: Number of Participants With Dose-Limiting Toxicity at Day 281, Number of Participants With Treatment-Emergent Adverse Events by Severity at Day 281 and 5 more. Started Nov 2017; status: completed.
02
Drugs
PF-06835375
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT03334851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03334851.